drugset / Trial / NCT06265428

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

NCT06265428

Phase 3 Active not recruiting 228 enrolled DualityBio Inc. BioNTech SE · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Timeline

Start
2024-01-29
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TRASTUZUMAB PAMIRTECAN Unknown Intravenous
Subject Trastuzumab emtansine Other / unclassified Intravenous